The ImmunoLogik wishes all people involved in the project, partners and supporters a merry Christmas and a happy New Year 2021.
Withou a doubt 2020 was a special year for everyone and in particular for ImmunoLogik, which is engaged in the fight against virusinfections. We are grateful for the support received and various engagement from countless companions in 2020. This gives us confidence to continue resolutely and with full vigor on the chosen path in future.
The ImmunoLogik and the university hospital Erlangen decided to continue their successful cooperation and agreed on an extension of the cooperation contract until September 2021.
Besides the managing director Christian Setz, Lars Siegert joins ImmunoLogik GmbH a managing director. With this step the shareholders give an important impulse for the direction of the successful development of the company with two managing directors from science and business.
In the fight against coronaviruses the team of the ImmunoLogik identified a promising lead candidate for the treatment of people infected with SARS-CoV-2. The highly qualified ImmunoLogik Team around Dr. Christian Setz (Managing Director, formerly project leader at the Institute for Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen-Nuremberg) and the scientific advisor Prof. Dr. Ulrich Schubert (Professor for virology at the Institute for Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen-Nuremberg) present this funding project on aescuvest.de in summer 2020. Only here you have the chance to learn more about the concept, to use the information advantage and to become an investor.
In the fight against coronaviruses the team of the ImmunoLogik identified a promising lead candidate for the treatment of people infected with SARS-CoV-2.
For the funding of the next steps in the drug development of the lead candidate IML-206 the ImmunoLogik starts a new crowdinvesting campaign on aescuvest.de and moneywell.de in the context of the #CrowdBeatsCorona alliance.
It is a great pleasure to have received the message from the USA, that the in July 2015 filed patent for IML-106 has been approved after long scrutiny by the US patent office this March. The patent extents to the substance IML-106 for the treatment HIV infections and AIDS.